Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250387) titled 'Fabhalta Capsules specified drug-use survey (C3 glomerulopathy)' on Sept. 25.
Study Type: Observational
Primary Sponsor: Sato Masayuki
Condition:
C3 glomerulopathy
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 31/07/2025
Target Sample Size: 27
To know more, visit https://jrct.mhlw.go.jp/latest-detail/jRCT2031250387
Published by HT Digital Content Services with permission from Health Daily Digest....